Literature DB >> 9493484

Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients.

R D Nebes1, B G Pollock, B H Mulsant, M A Kirshner, E Halligan, M Zmuda, C F Reynolds.   

Abstract

Depressed geriatric patients show substantial intersubject variability in cognitive performance, which complicates attempts to evaluate the cognitive effects of depression and of antidepressant therapy. This variability may reflect the multiple medications older patients take, many of which have anticholinergic effects. This study examined whether serum anticholinergicity (SA) explained some of the variability in depressed geriatric patients' memory performance. Before starting antidepressant treatment, 36 elderly depressed subjects were given a verbal learning test. At the same time, a blood sample was taken and analyzed by radioreceptor binding assay to determine their SA level. Nineteen of the subjects had detectable levels (mean = 0.28 pmole atropine equivalent). Subjects with an SA of zero showed significantly better delayed recall than did those with a positive SA level. Thus, even very low SA may produce subtle decrements in memory performance, an area of cognition known to be highly sensitive to anticholinergic effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9493484

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  8 in total

Review 1.  Drug-induced cognitive impairment in the elderly.

Authors:  A R Moore; S T O'Keeffe
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

2.  Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline.

Authors:  Michelle E Culang-Reinlieb; Joel R Sneed; John G Keilp; Steven P Roose
Journal:  Int J Geriatr Psychiatry       Date:  2011-09-15       Impact factor: 3.485

Review 3.  Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.

Authors:  Daniel M I Britt; Gregory S Day
Journal:  Mo Med       Date:  2016 May-Jun

4.  Aging changes and medical complexity in late-life bipolar disorder: emerging research findings that may help advance care.

Authors:  Martha Sajatovic; Brent P Forester; Ariel Gildengers; Benoit H Mulsant
Journal:  Neuropsychiatry (London)       Date:  2013-12-01

5.  The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

Authors:  Sophia Vinogradov; Melissa Fisher; Heather Warm; Christine Holland; Margaret A Kirshner; Bruce G Pollock
Journal:  Am J Psychiatry       Date:  2009-07-01       Impact factor: 18.112

Review 6.  The cognitive impact of anticholinergics: a clinical review.

Authors:  Noll Campbell; Malaz Boustani; Tony Limbil; Carol Ott; Chris Fox; Ian Maidment; Cathy C Schubert; Stephanie Munger; Donna Fick; David Miller; Rajesh Gulati
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

7.  Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium.

Authors:  Christine Thomas; Ute Hestermann; Juergen Kopitz; Konstanze Plaschke; Peter Oster; Martin Driessen; Christoph Mundt; Matthias Weisbrod
Journal:  BMC Neurosci       Date:  2008-09-15       Impact factor: 3.288

Review 8.  Serum Anticholinergic Activity and Cognitive and Functional Adverse Outcomes in Older People: A Systematic Review and Meta-Analysis of the Literature.

Authors:  Mohammed Saji Salahudeen; Te-Yuan Chyou; Prasad S Nishtala
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.